Triazolopyridine compounds as PIM kinase inhibitors
US8575145B2 · kind B2 · utility
2Cited by
0References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 18, 2009 |
| Grant date | Nov 5, 2013 |
| Priority date | — |
| Expiry date | Jul 11, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of Formula (I), in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.